Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people starting Wegovy notice shifts in how they feel emotionally, not just physically. Mood changes on semaglutide are real, reported in clinical trials, and worth understanding clearly before you begin treatment. They range from improved wellbeing as weight falls to, less commonly, low mood or anxious thoughts in the early weeks. Wegovy is a prescription-only medicine; a clinician assesses whether it is appropriate for you before any prescription is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The relationship between Wegovy and mood is not a simple one, and the honest answer is that the evidence points in both directions. In the STEP 1 trial (68 weeks, semaglutide 2.4mg versus placebo in nearly 2,000 adults) participants reported improvements in health-related quality of life scores, including emotional wellbeing, as their weight fell. That finding has been consistent across the broader STEP programme.
At the same time, the product information for Wegovy includes depression, suicidal ideation and mood changes as effects that have been reported. These are not common, but they are recognised. The MHRA and Novo Nordisk list them because people taking semaglutide have reported them, and that warrants transparency, not alarm.
One useful way to think about it: GLP-1 receptors exist in the brain, not only in the gut. Semaglutide acts on receptors involved in dopamine pathways and reward signalling, which is part of why it reduces food cravings so effectively. Those same central effects mean it can, in some people, influence how they feel beyond appetite. If you want to understand how semaglutide interacts with mood at a physiological level, that detail is covered before you start, not after.
Most people who notice mood changes during the first few weeks on Wegovy describe something relatively mild: a flattening of the usual food-related pleasure, occasional irritability around the time of a dose, or a low period that lifts within a few days. These tend to occur early in treatment, often alongside nausea and other gastrointestinal symptoms, and settle as the body adjusts.
A smaller number of people report a more sustained low mood, emotional blunting, or (rarely) thoughts of harming themselves. These need prompt medical attention. The rule is straightforward: if your mood feels consistently lower than usual for more than a few days, or if you have any thoughts of self-harm at any point, contact your prescriber without delay. Do not wait for a scheduled review.
It is also worth separating Wegovy's effect from other things happening at the same time. Significant dietary change can affect mood independently. Eating less, adapting to new habits, and the emotional weight of managing a health condition all interact. A question our prescribers hear fairly often is whether low mood is the medicine or something else entirely, and the honest answer is that it can be difficult to tell without a clinical conversation. For a fuller picture of the emotional side of treatment, the wegovy mood change page goes into greater depth on this.
During treatment with Wegovy, you should tell your prescriber about any of the following: persistent low mood lasting more than a few days, a noticeable loss of interest in things you normally enjoy, significant anxiety that feels new or worse than usual, and any thoughts of self-harm, however fleeting.
You can also report suspected side effects directly to the MHRA via the Yellow Card scheme. This is particularly valuable for newer medicines like Wegovy, where real-world reporting builds the evidence base that regulators use to update guidance.
If things feel urgent and you cannot reach your prescriber, NHS 111 is available around the clock, and the Samaritans are reachable on 116 123 at any time. The full side-effect profile for Wegovy covers the physical and emotional effects in one place if you want to read more broadly.
It would be misleading to frame Wegovy as purely a mood risk. A substantial body of evidence (including data from STEP 1, published in the New England Journal of Medicine) shows that many people feel meaningfully better in themselves as they lose weight. Improved mobility, better sleep, reduced joint pain, and lower blood pressure all contribute to a general sense of feeling well. For people who have struggled with weight for years, that shift can be significant.
Some participants also describe a quieter relationship with food: fewer intrusive thoughts about eating, less guilt, less of the exhausting internal negotiation that accompanies chronic dieting. Whether that counts as improved mood is partly semantic, but it is a real change in how people experience their days.
If you are thinking about Wegovy and have a history of depression, anxiety, or eating difficulties, that history is part of the clinical assessment, and our page on whether Wegovy affects your mood is a good place to read through before your consultation. The Wegovy overview page covers eligibility and how the consultation works. For a practical sense of what private treatment involves, including Wegovy pricing explained honestly, those pages answer the most common questions.
Whether the benefit-risk balance is right for you is something a prescriber decides with you, not for you. If you want that conversation, you can start your free consultation with our clinical team today. There is no obligation, and the assessment is thorough.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.